帕博利珠单抗治疗晚期非小细胞肺癌的系统评价再评价

doi:10.20047/j.issn1673-7210.2023.14.23

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (638 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To re-evaluate the quality of published systematic reviews of Pembrolizumab for advanced non-small cell lung cancer. Methods Systematic reviews of Pembrolizumab for advanced non-small cell lung cancer were collected from PubMed, EMBase, Cochrane Library, Web of Science, CNKI, VIP, and Wanfang databases from to February 2022. PRISMA statement, AMSTAR 2 and GRADE tools were used to evaluate the reporting quality, methodological quality, and evidence quality of the included systematic reviews. Results A total of ten systematic reviews were included. The PRISMA score ranged from 20-26. The evaluation results of AMSTAR 2 tool indicated that eight items were reported completely, two items were not reported. The grading results of GRADE showed that the outcome indexes of systematic reviews were mainly of low quality. Conclusion Current evidence shows that Pembrolizumab has significant clinical benefits in the treatment of advanced non-small cell lung cancer. However， the methodological quality of systematic reviews is insufficient， and the evidence quality of evidence-based medicine needs to be further improved.

Key words： Pembrolizumab Non-small cell lung cancer Systematic review Re-evaluation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Bing1 WAN Ning1
	2 XIE Fei2 YANG Ning3 XU Xiaoling1 LIANG Hongyi2 JI Bo2 YUAN Jin1

Cite this article:

WANG Bing1 WAN Ning1,2 XIE Fei2 YANG Ning3 XU Xiaoling1 LIANG Hongyi2 JI Bo2 YUAN Jin1. Re-evaluation of systematic reviews and meta analyses of Pembrolizumab treatment of advanced non-small cell lung cancer[J]. 中国医药导报, 2023, 20(14): 106-110.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.14.23 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I14/106

[1] 刘宗超，李哲轩，张阳，等.2020全球癌症统计报告解读[J].肿瘤综合治疗电子杂志，2021，7（2）：1-14.
[2] Zhang S，Sun K，Zheng R，et al.Cancer incidence and mortality in China，2015 [J]. Journal of the National Cancer Center，2020.
[3] Schenk EL，Patil T，Pacheco J，et al. 2020 Innovation-Based Optimism for Lung Cancer Outcomes [J]. Oncologist，2021，26（3）：e454-e472.
[4] 晁志祥，秦西淳，贾才力，等.色素上皮衍生因子及其多肽对非小细胞肺癌增殖、凋亡及迁移的影响[J].中国肺癌杂志，2021，24（12）：829-837.
[5] 花蕾，王榕林，苏海川.免疫检查点抑制剂治疗非小细胞肺癌的研究进展[J].中国医药导报，2022，19（5）：32-35，51.
[6] Shen X，Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer：meta-analysis [J]. BMJ，2018，362：k3529.
[7] Lipson EJ，Forde PM，Hammers HJ，et al. Antagonists of PD-1 and PD-L1 in Cancer Treatment [J]. Semin Oncol，2015， 42（4）：587-600.
[8] Hutton B，Salanti G，Caldwell DM，et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions：checklist and explanations [J]. Ann Intern Med，2015，162（11）：777-784.
[9] 张方圆，沈傲梅，曾宪涛，等.系统评价方法学质量评价工具AMSTAR 2解读[J].中国循证心血管医学杂志，2018，10（1）：14-18.
[10] Guyatt G，Oxman AD，Akl EA，et al. GRADE guidelines：1.Introduction-GRADE evidence profiles and summary of findings tables [J]. J Clin Epidemiol，2011，64（4）：383-394.
[11] Wang L，Yang Y，Yu J，et al. Efficacy and safety of anti- PD-1/PD-L1 in combination with chemotherapy or not as first-line treatment for advanced non-small cell lung cancer：A systematic review and network meta-analysis.Thorac Cancer，2022，13（3）：322-337.
[12] 雷玮成，杜宝萍，刘澍，等.帕博利珠单抗用于晚期非小细胞肺癌的有效性和安全性的Meta分析[J].今日药学，2021，31（8）：581-586.
[13] Liu J，Li C，Seery S，et al. Identifying optimal first-line inte- rventions for advanced non-small cell lung carcinoma according to PD-L1 expression：a systematic review and network meta-analysis [J]. Oncoimmunology，2020，9（1）：1746112.
[14] 余克富，叶佳丹，田月，等.帕博利珠单抗治疗非小细胞肺癌的Meta分析[J].医药导报，2020，39（12）：1684-1688.
[15] Wang C，Qiao W，Jiang Y，et al. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer：A systematic review and meta-analysis [J]. J Cell Physiol，2020，235（5）： 4913-4927.
[16] Addeo A，Banna GL，Metro G，et al. Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First- Line Treatment of Patients With Advanced Non-small Cell Lung Cancer：A Systematic Review and Literature-Based Meta-Analysis [J]. Front Oncol，2019，9：264.
[17] Liu T，Ding S，Dang J，et al. First-line immune checkpoint inhibitors for advanced non-small cell lung cancer with wild-type epidermal growth factor receptor （EGFR） or anaplastic lymphoma kinase （ALK）：a systematic review and network meta-analysis [J]. J Thorac Dis，2019，11（7）：2899-2912.
[18] Frederickson AM，Arndorfer S，Zhang I，et al. Pembrolizumab plus chemotherapy for first-line treatment of metastatic nonsquamous non-small-cell lung cancer：a network meta-analysis [J]. Immunotherapy，2019，11（5）：407-428.
[19] Kim R，Keam B，Hahn S，et al. First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chem- otherapy Alone in Non-small-cell Lung Cancer：A Systematic Review and Network Meta-analysis [J]. Clin Lung Cancer，2019，20（5）：331-338.
[20] Zhou Y，Lin Z，Zhang X，et al. First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression：pembrolizumab or pembrolizumab plus chemotherapy [J]. J Immunother Cancer，2019，7（1）：120.
[21] 陈芝强，李泽云，黄睿澜，等.晚期非小细胞肺癌患者PD-1使用的系统评价再评价[J].中国肿瘤，2021，30（6）：465-480.
[22] Pussegoda K，Turner L，Garritty C，et al. Systematic review adherence to methodological or reporting quality[J].Syst Rev,2017，6（1）：131.
[23] 田金徽.系统评价再评价撰写注意事项[J].中国药物评价，2019，36（1）：1-4.
[24] 倪萍，时景璞.系统评价与Meta分析再评价方法的更新及展望[J].中国循证心血管医学杂志，2018，10（10）：1170-1174.
[25] 藕顺龙，李幼平，喻佳洁，等.PD-1抑制剂治疗恶性黑色素瘤：系统评价再评价[J].中国医院药学杂志，2021， 41（7）：710-715.